Thanks for the reminder of the Maraviroc safety is

Thanks for the reminder of the Maraviroc safety issues. It appears that nearly all the contenders, excepting of course Leronlimab, have significant safety issues.

I am trying to retrace my investigational steps, but I am pretty certain that I read that the allosteric modulation of Maraviroc and similar small molecule disable the normal CCR5 functions, whereas Leronlimab does not.

All of this is well beyond the biology I learned in college, so I am trying to appreciate how much of a concern that Maraviroc presents as a competitor, separate from the known toxicity.

My basic understanding leads me to believe that it will be a very distant also ran, but time will tell.